Approximately 37% of the healthy Emirati cohort were classified as intermediate or poor CYP2C19 metabolizers, suggesting a high proportion may require alternative anti-platelet therapy instead of clopidogrel.
Cross-Sectional (n=298)
Yes
A significant proportion of the Emirati population carries genetic variants affecting clopidogrel metabolism, highlighting the potential utility of preemptive pharmacogenetic testing to guide antiplatelet therapy.
BACKGROUND: Clopidogrel is a widely prescribed prodrug that requires activation via specific pharmacogenes to exert its anti-platelet function. Genetic variations in the genes encoding its transporter, metabolizing enzymes, and target receptor lead to variability in its activation and platelet inhibition and, consequently, its efficacy. This variability increases the risk of secondary cardiovascular events, and therefore, some variations have been utilized as genetic biomarkers when prescribing clopidogrel. METHODS: Our study examined clopidogrel-related genes (CYP2C19, ABCB1, PON1, and P2Y12R) in a cohort of 298 healthy Emiratis individuals. The study used whole exome sequencing (WES) data to comprehensively analyze pertinent variations of these genes, including their minor allele frequencies, haplotype distribution, and their resulting phenotypes. RESULTS: Our data shows that approximately 37% (n = 119) of the cohort are likely to benefit from the use of alternative anti-platelet drugs due to their classification as intermediate or poor CYP2C19 metabolizers. Additionally, more than 50% of the studied cohort exhibited variants in ABCB1, PON1, and P2YR12 genes, potentially influencing clopidogrel's transport, enzymatic clearance, and receptor performance. CONCLUSIONS: Recognizing these alleles and genotype frequencies may explain the clinical differences in medication response across different ethnicities and predict adverse events. Our findings underscore the need to consider genetic variations in prescribing clopidogrel, with potential implications for implementing personalized anti-platelet therapy among Emiratis based on their genetic profiles.
Khasawneh et al. (Wed,) conducted a cross-sectional in Healthy individuals (pharmacogenomic screening) (n=298). Pharmacogenomic screening (CYP2C19, ABCB1, PON1, P2Y12R) was evaluated on Prevalence of intermediate or poor CYP2C19 metabolizers. Approximately 37% of the healthy Emirati cohort were classified as intermediate or poor CYP2C19 metabolizers, suggesting a high proportion may require alternative anti-platelet therapy instead of clopidogrel.